Nanotechnology Department, School of Advanced Technologies, Iran University of Science and Technology, Tehran, Iran.
Australasian Nanoscience and Nanotechnology Initiative (ANNI), Monash University LPO, Clayton, VIC 3168, Australia.
Curr Pharm Des. 2024;30(36):2850-2881. doi: 10.2174/0113816128304923240704113319.
In order to improve the treatment of lung cancer, this paper looks at the development of cisplatinbased liposomal nanocarriers. It focuses on addressing the drawbacks of conventional cisplatin therapy, including systemic toxicity, inadequate tumor targeting, and drug resistance. Liposomes, or spherical lipid vesicles, offer a potentially effective way to encapsulate cisplatin, enhancing its transport and minimizing harmful effects on healthy tissues. The article discusses many liposomal cisplatin formulations, including pH-sensitive liposomes, sterically stabilized liposomes, and liposomes coupled with specific ligands like EGFR antibodies. These novel formulations show promise in reducing cisplatin resistance, optimizing pharmacokinetics, and boosting therapeutic results in the two in vitro and in vivo models. They also take advantage of the Enhanced Permeability and Retention (EPR) effect in the direction of improved tumor accumulation. The study highlights the need for more investigation to move these liposomal formulations from experimental to clinical settings, highlighting their potential to offer less harmful and more effective cancer therapy alternatives.
为了改善肺癌的治疗效果，本文着眼于顺铂类脂质体纳米载体的发展。它专注于解决传统顺铂治疗的缺点，包括全身毒性、肿瘤靶向不足和耐药性。脂质体或球形脂质囊泡提供了一种封装顺铂的有效方法，可增强其输送并最大程度地减少对健康组织的有害影响。本文讨论了许多顺铂脂质体制剂，包括 pH 敏感脂质体、空间稳定脂质体和与特定配体（如 EGFR 抗体）偶联的脂质体。这些新型制剂在降低顺铂耐药性、优化药代动力学和提高两种体外和体内模型的治疗效果方面显示出前景。它们还利用了增强的通透性和保留（EPR）效应，以促进肿瘤的积累。该研究强调需要进一步研究，将这些脂质体制剂从实验环境推向临床环境，突出其提供毒性更低、更有效的癌症治疗替代方案的潜力。
